Invitation

Please click on the Session title to see the official invitation. (As agreed upon..., links are not available)

13:00 - 14:30

NOVARTIS - Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: what the neurologist needs to know

BIOGEN - MULTIPLE SCLEROSIS DIAGNOSTIC CHALLENGES AND COGNITIVE IMPAIRMENT IN A CHANGING WORLD

AVEXIS -Gene therapy in neuromuscular diseases: a journey from bench to bedside

ALNYLAM PHARMACEUTICALS - Hereditary transthyretin amyloidosis (hATTR) Unraveled: Linking a Mixed Presentation to One Disease

12:15 - 13:15

NOVARTIS - Relentless in Multiple Sclerosis: the continuing mission to stop disease activity

BIOGEN - Spinal muscular atrophy in adults: patient management in the new therapeutic era

13:00 - 14:30

SANOFI GENZYME - Novel tales of the unexpected: Uncovering the path to earlier diagnosis in muscular diseases

13:45 - 14:45

TEVA - OPTIMISM AND OPPORTUNITIES WITH ANTI-CGRP (Calcitonin Gene-Related Peptide) BIOLOGICS IN MIGRAINE - WHERE ARE WE TODAY?

ROCHE - The Multiple Sclerosis paradigm - can we do better?

BIAL - Beyond motor wearing-OFF: What have we learned?

18:30 - 20:00

SUNOVION - From "OFF" To "ON" - Treating "OFF" Episodes In Parkinson's Disease

ELI LILLY - Successfully navigating the practice of migraine prevention

UCB - Childhood to adulthood transition in Neurology: How to best orchestrate the transition within epilepsy

12:15 - 13:15

CELGENE - Therapeutic Inertia in Multiple Sclerosis: A Call to Action!

ZAMBON - Optimizing levodopa therapy: searching for the evidence, looking beyond the data

13:00 - 14:30

AKCEA - Navigating the Accurate Diagnosis of Rare Neuropathies

ALEXION - How can we improve patient outcomes in difficult-to-treat myasthenia gravis? An interactive discussion

13:45 - 14:45

MERCK - Recent advancements in the management of relapsing multiple sclerosis

EVERPHARMA - Innovative treatment options for Traumatic Brain Injuries (TBI)

18:30 - 20:00

ABBVIE - Optimizing Care in Advanced Parkinson's Disease - Past Insights, Current Practices, and Future Prospects

10:00 - 10:30

SANOFI GENZYME - Multiple Sclerosis, out of the Brain?

16:15 - 16:45

CELGENE - How to Interpret Published Data

09:30 - 10:00

CELGENE - How to Apply McDonald 2017 Criteria?

16:15 - 16:45

SANOFI GENZYME - Normal brain atrophy rates in Multiple Sclerosis, a brainwave?

09:30 - 10:00

SANOFI GENZYME - Wrap your brain around quality of life in Multiple Sclerosis

10:00 - 10:30

CELGENE - Are Brain Atrophy and Cognition Important in the Treatment of Early Multiple Sclerosis

16:15 - 16:30

ROCHE -Early Alzheimer's disease: Towards drug-biomarker co-development

16:30 - 16:45

MERCK - Family planning for patients with multiple sclerosis

09:30 - 09:45

ALNYLAM PHARMACEUTICALS - Acute hepatic porphyria: A potentially fatal cause of peripheral neuropathy or encephalopathy A practical perspective from an expert center.

09:45 - 10:00

MERCK - Cladribine Tablets real-world experience: the Finnish experience

16:15 - 16:30

ROCHE - Understanding spinal muscular atrophy: how far have we come?

16:30 - 16:45

VIELA BIO - N-Momentum Study Design

09:45 - 10:00

ROCHE - Huntington's Disease

16:15 - 16:30

MERCK - Multiple Sclerosis